Microsporum gypseum (M. gypseum)

Microsporum gypseum is a geophilic dermatophyte fungus that primarily resides in soil but is capable of causing superficial fungal infections, such as tinea corporis and tinea capitis, in humans and animals (StatPearls, 2023). Unlike many common anthropophilic dermatophytes, M. gypseum often triggers a more robust inflammatory response in the host due to its soil-based origin. From a pharmacological standpoint, M. gypseum is an infectious pathogen rather than a single molecular target, though it contains several essential enzymes that are the focus of antifungal therapy (Mycology Online, 2024). The primary therapeutic approach involves disrupting the fungal cell membrane by inhibiting the ergosterol biosynthesis pathway, specifically targeting the enzymes squalene epoxidase and lanosterol 14-alpha demethylase (NCBI Bookshelf, 2023). Commonly utilized drugs include allylamines like terbinafine and various azoles such as itraconazole and ketoconazole (PubMed, PMID: 28884241). Additionally, the organism produces keratinases that allow it to colonize keratinized tissues like hair and skin, which are critical to its pathogenicity (PubMed, PMID: 30204595). Understanding the molecular characteristics of this fungus is essential for biotech researchers focusing on broad-spectrum antifungal development and diagnostic identification.

Other names

Nannizzia gypseaArthroderma gypseumGeophilic dermatophyte

Antifungal agents targeting Microsporum gypseum act by inhibiting ergosterol biosynthesis through the inhibition of squalene epoxidase (allylamines) or lanosterol 14-alpha demethylase (azoles), leading to membrane disruption, or by inhibiting fungal mitosis through tubulin binding (griseofulvin).